Moderna CFO Mock James M exercised Options for 19,836 shares at $30.96 per share, then sold 34,836 shares at $134.49. The transactions left him with 59,375 shares and 43,642 derivative securities, while the exercise represented 21.1% of his resulting share holding and 31.2% of his prior derivative position.
Key Highlights
- Mock James M exercised options for 19,836 shares at $30.96 per share on 10 September 2026.
- Mock James M held 43,642 derivative securities after exercising the options.
- The sales left the Moderna CFO with 59,375 shares.
Moderna, Inc. (NASDAQ: MRNA) Chief Financial Officer Mock James M exercised options for 19,836 shares at $30.96 per share on 10 September 2026. The transaction was recorded alongside sales totaling 34,836 shares at $134.49 per share.
Moderna Option Exercise and Share Transactions
Transaction code M identifies an option exercise, while code S identifies a sale. The option exercise left Mock James M with 94,211 shares, and the transaction represented about 21.1% of that resulting share holding. The sales involved 34,836 shares priced at $134.49 per share, after which his share balance was 59,375. His derivative-securities balance following the exercise was 43,642. The exercise represented about 31.2% of his prior derivative-securities holding.
FAQs
Q: What did Moderna CFO Mock James M do with MRNA shares?
A: Mock James M exercised options for 19,836 Moderna shares at $30.96 per share. He also sold 34,836 shares at $134.49 per share on 10 September 2026.
Q: How many Moderna shares did the CFO own after the transactions?
A: Following the two sales, Mock James M owned 59,375 Moderna shares. Before those sales, his share holding after the option exercise was 94,211 shares.
Q: What happened to Mock James M’s Moderna derivative securities?
A: The Moderna CFO held 43,642 derivative securities after exercising the options. The exercise represented about 31.2% of his prior derivative-securities holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.